Internal Medicine, Gastroenterology · Baltimore, MD
NPI
1104094739
Since 2008
Specialty
Internal Medicine, Gastroenterology
Code 207RG0100X
Group practices
1
Medicare group memberships
Hospitals
3
Hospital affiliations
600 N Wolfe St, 1830 Bldg, Rm 420
Baltimore, MD, 21287
Phone (410) 614-6708
Groups this clinician bills Medicare through
Medicare paid, 2024
$575K
35,473 services
Medicare patients, 2024
431
Average age 71
Drug cost, 2024
$6.7M
911 prescriptions
Company payments, 2025
$2,545
From 21 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Mark G Lazarev was code J3380 (injection, vedolizumab, intravenous, 1 mg), 14,100 times for 18 patients. In total Mark G Lazarev billed 35,473 services in 53 codes, and Medicare paid $575K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2013-02-11.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J3380 Injection, vedolizumab, intravenous, 1 mg | Office | 14,100 | 18 | $17.01 | $240K |
| J0897 Injection, denosumab, 1 mg | Office | 2,040 | 28 | $20.22 | $41K |
| J3489 Injection, zoledronic acid, 1 mg | Office | 255 | 51 | $5.03 | $1,283 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 206 | 145 | $12.87 | $2,651 |
| 96413 Chemotherapy Administration | Office | 140 | 54 | $104.73 | $15K |
| 99213 Office E&M - Established | Office | 131 | 105 | $67.03 | $8,782 |
| 99214 Office E&M - Established | Office | 94 | 69 | $99.51 | $9,354 |
| 96365 Intravenous Infusion, Hydration | Office | 76 | 69 | $51.98 | $3,950 |
| 96415 Chemotherapy Administration | Office | 64 | 24 | $23.12 | $1,479 |
| 45380 Lower GI Endoscopy - Other | Facility | 62 | 62 | $123.09 | $7,632 |
| 99231 Hospital E&M - Subsequent | Facility | 34 | 28 | $40.39 | $1,373 |
| 96372 Injection Administration | Office | 34 | 28 | $11.59 | $394 |
| 45385 Colonoscopy - Lesion Removal | Facility | 34 | 34 | $196.57 | $6,683 |
| 43239 Upper GI Endoscopy | Facility | 31 | 31 | $91.70 | $2,843 |
| 99221 Hospital E&M - Initial | Facility | 20 | 20 | $64.44 | $1,289 |
By year: 2022 $380K for 30,032 services; 2023 $489K for 27,999 services; 2024 $575K for 35,473 services.
Medicare prescription drug claims, 2024
In 2024, the drug Mark G Lazarev prescribed most often to Medicare patients was Stelara (Ustekinumab), with 164 prescriptions and refills. In total Mark G Lazarev wrote 911 Medicare prescriptions that cost $6.7M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Stelara Ustekinumab | 164 | 233 | 22 | $4.8M |
| Mesalamine Generic | 93 | 248 | 27 | $86K |
| Omeprazole Generic | 54 | 120 | 20 | $788 |
| Diphenoxylate-Atropine Diphenoxylate Hcl/Atropine | 41 | 47 | Under 11 | $1,317 |
| Remicade Infliximab | 36 | 41 | Under 11 | $324K |
| Pantoprazole Sodium Generic | 33 | 91 | 11 | $445 |
| Ondansetron Odt Ondansetron | 31 | 31 | Under 11 | $482 |
| Famotidine Generic | 30 | 79 | 11 | $633 |
| Skyrizi On-Body Risankizumab-Rzaa | 23 | 43 | Under 11 | $429K |
| Humira(Cf) Adalimumab | 22 | 22 | Under 11 | $185K |
| Mesalamine Er Mesalamine | 19 | 32 | Under 11 | $5,498 |
| Prednisone Generic | 17 | 19 | Under 11 | $147 |
| Azathioprine Generic | 17 | 25 | Under 11 | $1,518 |
| Ciprofloxacin Hcl Generic | 16 | 28 | Under 11 | $459 |
| Tramadol Hcl Generic | 15 | 15 | Under 11 | $20.92 |
Brand drugs: - claims; generic drugs: 522 claims; opioid claims: 15.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Mark G Lazarev $2,545 ($2,545 in general payments such as food, travel and fees) from 21 companies. The largest payer was Abbvie Inc. with $471.
| Company | Payments | Amount |
|---|---|---|
| Abbvie Inc. ABBV | 31 | $471 |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 16 | $469 |
| Janssen Biotech, Inc. JNJ | 22 | $359 |
| Madrigal Pharmaceuticals MDGL | 7 | $261 |
| Celltrion USA Inc. 068270.KS | 19 | $199 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC BHC | 7 | $152 |
| Ipsen Biopharmaceuticals, Inc IPN.PA | 6 | $146 |
| Pfizer Inc. PFE | 6 | $115 |
| Ardelyx, Inc. ARDX | 2 | $50.76 |
| Lilly USA, LLC LLY | 2 | $42.68 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.